Jessica Marshal, APRN
Addiction Medicine · Lexington, KYNPI 1447793872
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $562 and has fallen 97.1% since, to $17 in 2025.
Across 15 payments — averaging $64.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GRT US Holding, Inc.$195
- Evoke Pharma, Inc.$125
- Paratek Pharmaceuticals, Inc.$100
- Gilead$90
- Idorsia Pharmaceuticals US Inc$80
- Biodelivery Sciences International, Inc.$76
- plus $298 from 6 others
What the payments were for
- Food & beverage$965100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GRT US Holding, Inc. | 2 | $195 |
| Evoke Pharma, Inc. | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 1 | $100 |
| Gilead | 1 | $90 |
| Idorsia Pharmaceuticals US Inc | 1 | $80 |
| Biodelivery Sciences International, Inc. | 1 | $76 |
| Redhill Biopharma Inc. | 1 | $71 |
| Alkermes, Inc. | 3 | $64 |
| AstraZeneca | 1 | $56 |
| Averitas Pharma Inc. | 1 | $46 |
| Emergent Biosolutions Inc. | 1 | $45 |
| Indivior Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$965 in reported general payments places this provider in the 60th percentile of 40 addiction medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $802 |
| Trazodone Hcl | 14 | $23 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Lexington
- Anastasia JandesLexington$55K
- Rallie McAllisterLexington$17K
- Michael KindredLexington$13K
- Ronald BibbLexington$508
- Richard BennettLexington$247
- Rebecca AtkinsLexington$21
- Gary HiggasonLexington$14
- Asad IsmailLouisville$10K
- Guy LernerElizabethtown$10K
- Joseph KoenigsmarkShepherdsville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.